Phase III trial of a non-myeloablative preparative regimen with fludarabine and busulfan with or without anti-lymphocyte antibodies (Campath-1H [alemtuzumab] or ATG [antithymocyte globulin]) for patients with acute myelogenous leukemia or myelodysplastic syndrome undergoing allogeneic stem cell transplantation from an HLA compatible donor

Trial Profile

Phase III trial of a non-myeloablative preparative regimen with fludarabine and busulfan with or without anti-lymphocyte antibodies (Campath-1H [alemtuzumab] or ATG [antithymocyte globulin]) for patients with acute myelogenous leukemia or myelodysplastic syndrome undergoing allogeneic stem cell transplantation from an HLA compatible donor

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 10 Apr 2011

At a glance

  • Drugs Alemtuzumab; Antithymocyte globulin; Busulfan; Ciclosporin; Fludarabine; Methotrexate
  • Indications Acute myeloid leukaemia; Graft-versus-host disease; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Apr 2011 Status changed from recruiting to withdrawn prior to recruitment, according to ClinicalTrials.gov. The principal investigator no londer works for Hadassah.
    • 03 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top